In August 2025, InSilico Medicine Hong Kong Limited announced a clinical trial is to learn about INS018_055 in adults with ...

MannKind saw decent growth from its two core products in Q2 and just signed a new non-dilutive financing agreement with ...

MAX BioPharma and Revilico Collaboration LOS ANGELES, CA / ACCESS Newswire / August 6, 2025 / Today MAX BioPharma, Inc. ( and ...

Key Points Revenue grew 10% year-over-year to $10.8 million (GAAP) in Q2 2025, reflecting continued top-line gains, with GAAP net revenues of $10.8 million. Adjusted diluted earnings per share ...

Operator: Good afternoon, and welcome to the Cumberland Pharmaceuticals Second Quarter 2025 Financial Report and Company ...

The 2025 World Bronchiectasis Conference highlighted new research on bronchiectasis and NTM - plus an emerging ...